Professional Documents
Culture Documents
ebook download Validamycin and its Derivatives. Discovery, Chemical Synthesis, and Biological Activity 1st Edition Edition Xiaolong Chen - eBook PDF all chapter
ebook download Validamycin and its Derivatives. Discovery, Chemical Synthesis, and Biological Activity 1st Edition Edition Xiaolong Chen - eBook PDF all chapter
ebook download Validamycin and its Derivatives. Discovery, Chemical Synthesis, and Biological Activity 1st Edition Edition Xiaolong Chen - eBook PDF all chapter
https://ebooksecure.com/download/carbohydrates-in-drug-discovery-
and-development-synthesis-and-application-ebook-pdf/
https://ebooksecure.com/download/n-sulfonated-n-heterocycles-
synthesis-chemistry-and-biological-applications-ebook-pdf/
https://ebooksecure.com/download/environmental-technology-and-
sustainability-physical-chemical-and-biological-technologies-for-
clean-environmental-management-ebook-pdf/
https://ebooksecure.com/download/wearable-physical-chemical-and-
biological-sensors-fundamentals-materials-and-applications-ebook-
pdf/
MCAT chemical and physical foundations of biological
systems, 2016 - eBook PDF
https://ebooksecure.com/download/mcat-chemical-and-physical-
foundations-of-biological-systems-2016-ebook-pdf/
https://ebooksecure.com/download/systems-immunology-and-
infection-microbiology-ebook-pdf/
https://ebooksecure.com/download/logarithm-and-its-applications-
ebook-pdf/
https://ebooksecure.com/download/imidazole-based-drug-discovery-
heterocyclic-drug-discovery-ebook-pdf/
Validamycin and Its Derivatives
Validamycin
and Its Derivatives
Discovery, Chemical Synthesis,
and Biological Activity
No part of this publication may be reproduced or transmitted in any form or by any means, electronic
or mechanical, including photocopying, recording, or any information storage and retrieval system, without
permission in writing from the publisher. Details on how to seek permission, further information about the
Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance
Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the Publisher
(other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden
our understanding, changes in research methods, professional practices, or medical treatment may become
necessary.
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and
using any information, methods, compounds, or experiments described herein. In using such information or
methods they should be mindful of their own safety and the safety of others, including parties for whom
they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume
any liability for any injury and/or damage to persons or property as a matter of products liability, negligence
or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the
material herein.
ISBN: 978-0-08-100999-4
An Introduction to Validamycins
and Their Derivatives
1.1 IMPORTANCE OF ANTIBIOTICS
The term “antibiotics” was first coined by the American microbiologist
Selman Waksman and his colleagues to describe chemical substances pro-
duced by microorganisms and having antagonistic effects on the growth of
other microorganisms. It excluded synthetic antimicrobials (sulfur drugs) and
biological products of nonmicrobial origin having antagonistic effects on bac-
teria. Though antibiotics were introduced into clinical practice only in the
middle of the 20th century, the use of microorganisms for the management of
microbial infections in ancient Egypt, Greece, China, and some other places
in the world is well documented. The modern era of antibiotics started with
the serendipitous discovery of penicillin from the culture filtrate of a fungus,
Penicillium notatum, by Alexander Fleming in 1928 (Fleming, 1929).
In the present scenario, antibiotics available in the market are either
produced by microbial fermentation or are derived via semisynthetic route
using the existing antibiotic backbone structure. They are classified into
different chemically defined groups. Antibiotics target bacterial physiology
and biochemistry, causing microbial cell death or the cessation of growth.
A significant number of these antibiotics affect cell walls or membranes
(e.g., β-lactam and glycopeptides), while several others exert their anti-
bacterial activity by targeting protein synthetic machinery via interaction
with ribosomal subunits, and these include antibiotics such as macrolides,
chloramphenicol, tetracycline, linezolid, and aminoglycosides. Other “mech-
anistic” groups include molecules that interfere with the nucleic acid
synthesis [e.g., fluoroquinolones (FQ) and rifampin], while some others exert
their effects by interfering with the metabolic pathways (e.g., sulfonamides
and folic acid analog) or by disruption of the bacterial membrane structure
(e.g., polymyxins, daptomycin, and others).
The successful use of antibiotics against bacterial diseases of human
beings has led to a large-scale screening of antibiotics’ effect for plant
disease control in the world.
Validamycin can also be used for the control of R. solani in potatoes, vegetables,
strawberries, tobacco, ginger, and other crops, and damping-off diseases of
cotton, rice and sugar beet, etc. Besides its excellent control effect, low price,
low drug-resistance, and low toxicity are the other outstanding merits of valida-
mycin, and it is now one of the most important agricultural antibiotics with the
biggest production in China (Shen, 1996).
Validamycin is a mixture of aminoglycoside compounds. There have
been eight members termed A to H (Fig. 1.1) (Asano et al., 1990; Horii
R5OH2C
R6O
OH HO
HO
HN
R3
OH
R1
R2OH2C
R4O
Compound R1 R2 R3 R4 R5 R6
Validamycin A H H H β-D-Glc H H
Validamycin B H H OH β-D-Glc H H
α-D-
Validamycin C H H H β-D-Glc H
Glc
Validamycin D H α-D-Glca H H H H
α-D-Glc(1-4)- β-
Validamycin E H H H H H
D-Glc
Validamycin G OH H H β-D-Glc H H
β-D-Glc(1-6)- β-
Validamycin H H H H H H
D-Glc
aGlc=Glucopyranosyl.
CH2OH CH2OH
CH2 OH
HO
OH OH OH NH2
NH2 OH NH2 OH
OH
OH OH OH
Valienamine Validamine Hydroxyvalidamine
CH 2OH CH2 OH
OH
OH OH
OH OH N
NH2 OH
OH H
OH OH OH
Valiolamine Voglibose
FIGURE 1.2 Chemical structures of valienamine and its related compounds.
et al., 1972; Iwasa et al., 1970; Kameda et al., 1986) isolated from the broth
of S. hygroscopicus var. limoneus, with validamycin A [1L-(1,3,4/2,6)-2,3-
dihydroxy-6-hydroxymethyl-4-[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-hydroxymethyl-
cyclohex-2-enylamino] cyclohexyl β-D-glucopyranoside] as the main member
and the most active. So the content of validamycin A is the most important
quality parameter of the commercial products of validamycin.
Many researchers also focused on the chemical synthesis, biosynthesis
genes, and derivatives of validamycins. Among them, the most interesting
work is that validamycins were lysed to produce valienamine or validamine
(Fig. 1.2) (Asano et al., 1984; Chen et al., 2005a, 2005b; Kameda et al.,
1980, 1981), which could be applied to synthesize valiolamine (Horii et al.,
1985; Kameda et al., 1984), and then voglibose (Babu et al., 2005; Chen
et al., 2006; Floss et al., 1999; Fukase, 1997; Kameda and Horii, 1986; Lu
et al., 2005; Yuan et al., 2005). Voglibose (code number: AO-128, trade
name: Basen), is an N-substituted derivative of valiolamine, which is a
branched-chain aminocyclitol, or pseudoamino sugar. Voglibose has attracted
considerable interest due to its wide range of therapeutic and pharmacologi-
cal properties, which include its excellent inhibitory activity against
α-glucosidases and its action against hyperglycemia and various disorders
caused by hyperglycemia. It has shown strong antiobesity and antidiabetic
activities, as it is a new, potent glucosidase inhibitor and is a drug used for
NIDDM (noninsulin-dependent diabetes mellitus) in Japan, China, and
Korea. Therefore, the industry of validamycin has converted from the agri-
cultural antibiotic to pharmaceutical.
Valienamine could also be used to synthesize N-octyl-4-epi-β-valienamine
(NOEV) (Iwasaki et al., 2006; Ogawa et al., 2004; Suzuki, 2006, 2008,
2013; Suzuki et al., 2007) and N-octyl-β-valienamine (NOV) (Ogawa et al.,
1996, 1998; Suzuki, 2013) (Fig. 1.3), two highly potent drug candidates
An Introduction to Validamycins and Their Derivatives Chapter | 1 5
OH OH
HO
H HO
H
HO N HO N
(CH2 )7 CH3 (CH2 )7 CH3
HO HO
NEOV NOV
FIGURE 1.3 Chemical structures of NEOV and NOV.
for chemical chaperone therapy. NOEV and NOV are promising thera-
peutic agents for human β-galactosidase deficiency disorders (GM1-
gangliosidosis and Morquio B disease) and β-glucosidase deficiency
disorders (phenotypic variations of Gaucher disease), respectively (Suzuki,
2013). Originally NOEV and NOV had been discovered as competitive
inhibitors, and then their paradoxical bioactivities as chaperones were
confirmed in cultured fibroblasts from patients with these disorders.
Subsequently, GM1-gangliosidosis model mice have been used for con-
firmation of clinical effectiveness, adverse effects, and pharmacokinetic
studies. Orally administered NOEV entered the brain through the blood
brain barrier enhanced β-galactosidase activity, reduced substrate storage,
and improved neurological deterioration clinically. Computational analysis
revealed pH-dependent enzyme chaperone interactions. The recent study
(Suzuki, 2013) indicated chaperone activity of a new 1-deoxygalactonojirimycin
derivative, MTD118, for β-galactosidase complementary to NOEV. NOV also
showed the chaperone effect toward several β-glucosidase gene mutants in
Gaucher disease. Furthermore a commercial expectorant drug, ambroxol, was
found to be a chaperone for β-glucosidase. A few Gaucher patients
responded to this drug with remarkable improvement of oculomotor dys-
function and myoclonus. It is hoped that chaperone therapy will become
available for some patients with Fabry disease, GM1-gangliosidosis,
Gaucher disease, and other lysosomal storage diseases particularly with
central nervous system involvement.
REFERENCES
Agricultural Antibiotic Group SIOAPS, 1975a. Classification and identification of jinggangmy-
cin producing strains. Weishengwu Xuebao 15 (2), 110 113.
Agricultural Antibiotic Group SIOAPS, 1975b. Isolation and identification of jinggangmycins.
Weishengwu Xuebao 15 (3), 223 226.
Asano, N., Kameda, Y., Matsui, K., Horii, S., Fukase, H., 1990. Validamycin H, a new pseudo-
tetrasaccharide antibiotic. J. Antibiot. 43 (8), 1039 1041.
Asano, N., Takeuchi, M., Ninomiya, K., Kameda, Y., Matsui, K., 1984. Microbial degradation
of validamycin A by Flavobacterium saccharophilum. Enzymatic cleavage of C N linkage
in validoxylamine A. J. Antibiot. (Tokyo) 37 (8), 859 867.
Babu J.S., Chavan G.J., Khanduri C.H., Kumar Y., Ray P.C., (Ranbaxy Laboratories Limited,
India). assignee. 2005 20050324. Processes for the purification of voglibose and the
preparation and purification of its intermediates. Application: WO patent 2005-IB777,
2005092834.
Chen, X., Zheng, Y., Shen, Y., 2005a. A new method for production of valienamine with micro-
bial degradation of acarbose. Biotechnol. Prog. 21 (3), 1002 1003.
Chen, X., Zheng, Y., Shen, Y., 2005b. Quantitative analysis of valienamine in the microbial deg-
radation of validamycin A after derivatization with p-nitrofluorobenzene by reversed-phase
high-performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life
Sci. 824 (1 2), 341 347.
Chen, X., Zheng, Y., Shen, Y., 2006. Voglibose (Basen, AO-128), one of the most important
alpha-glucosidase inhibitors. Curr. Med. Chem. 13 (1), 109 116.
Fleming, A., 1929. Classics in infectious diseases: on the antibacterial action of cultures of a
penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp.
Pathol. 10, 226 236.
Floss H.G., Lee S., Tornus I., (Bayer A.-G., Germany). assignee. 1999 19990329. Preparation of
valiolone as synthon for acarbose and voglibose. Application: WO patent 1999-EP2141,
9950217.
Fukase, H., 1997. Development of voglibose (Basen), an antidiabetic agent. Yuki Gosei Kagaku
Kyokaishi 55 (10), 920 925.
Horii, S., Fukase, H., Kameda, Y., 1985. Stereoselective conversion of valienamine and valida-
mine into valiolamine. Carbohydr. Res. 140 (2), 185 200.
Horii, S., Kameda, Y., Kawahara, K., 1972. Validamycins, new antibiotics. VIII. Isolation and
characterization of validamycins C, D, E, and F. J. Antibiot 25 (1), 48 53.
An Introduction to Validamycins and Their Derivatives Chapter | 1 7
Iwasa, T., Yamamoto, H., Shibata, M., 1970. Validamycins, new antibiotics. I. Streptomyces
hygroscopicus var. limoneus nov. var., validamycin-producing organism. J. Antibiot.
(Tokyo) 23 (12), 595 602.
Iwasaki, H., Watanabe, H., Iida, M., Ogawa, S., Tabe, M., Higaki, K., et al., 2006. Fibroblast
screening for chaperone therapy in beta-galactosidosis. Brain Dev. 28 (8), 482 486.
Kameda, Y., Asano, N., Teranishi, M., Matsui, K., 1980. New cyclitols, degradation of valida-
mycin A by Flavobacterium saccharophilum. J. Antibiot. 33 (12), 1573 1574.
Kameda, Y., Asano, N., Teranishi, M., Yoshikawa, M., Matsui, K., 1981. New intermediates,
degradation of validamycin A by Flavobacterium saccharophilum. J. Antibiot. 34 (9),
1237 1240.
Kameda, Y., Asano, N., Yamaguchi, T., Matsui, K., Horii, S., Fukase, H., 1986. Validamycin G
and validoxylamine G, new members of the validamycins. J. Antibiot. 39 (10), 1491 1494.
Kameda, Y., Asano, N., Yoshikawa, M., Takeuchi, M., Yamaguchi, T., Matsui, K., et al., 1984.
Valiolamine, a new alpha-glucosidase inhibiting aminocyclitol produced by Streptomyces
hygroscopicus. J. Antibiot. (Tokyo) 37 (11), 1301 1307.
Kameda Y., Horii S.; (Takeda Chemical Industries, Ltd., Japan). assignee. 1986 19860423.
Valiolamine derivatives. Application: EP patent 1986-303048, 199591.
Kumar, K., Gupta, S.C., Chander, Y., Singh, A.K., 2005. Antibiotic use in agriculture and its
impact on the terrestrial environment. Adv. Agron. 87 (05), 1 54.
Lu, C., Ye, W., Hu, S., Pan, Y., Yuan, J., 2005. Preparation of voglibose from valiolamine.
Zhongguo Yiyao Gongye Zazhi 36 (9), 525.
Mcmanus, P., Stockwell, V., 2000. Antibiotics for plant diseases control: silver bullets or rusty
sabers. Core Discussion Papers Rp (May), 27 51.
Misato, T., 1976. The development of agricultural antibiotics. Environ. Qual. Safety 5 (5),
48 55.
Ogawa, S., Ashiura, M., Uchida, C., Watanabe, S., Yamazaki, C., Yamagishi, K., et al., 1996.
Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienamines. Bioorg. Med.
Chem. Lett 6 (8), 929 932.
Ogawa, S., Kobayashi, Y., Kabayama, K., Jimbo, M., Inokuchi, J.-I., 1998. Chemical modifica-
tion of β-glucocerebrosidase inhibitor N-octyl-β-valienamine: synthesis and biological evalu-
ation of N-alkanoyl and N-alkyl derivatives. Bioorg. Med. Chem. 6 (10), 1955 1962.
Ogawa, S., Sakata, Y., Ito, N., Watanabe, M., Kabayama, K., Itoh, M., et al., 2004. Convenient
synthesis and evaluation of glycosidase inhibitory activity of α- and β-galactose-type valie-
namines, and some N-alkyl derivatives. Bioorg. Med. Chem. 12 (5), 995 1002.
Shen, Y.C., 1996. Research and development on jinggangmycins for 25 years. Zhiwu Baohu
(Plant Protect.) 22 (4), 44 45.
Shibata, M., Kido, Y., Honda, Y., Shimizu, K., 1989. Hyphal extension inhibitors I and II with
similar inhibitory spectra to validamycin, isolated from hyphae of Rhizoctonia solani. Agric.
Biol. Chem. 53 (3), 869 873.
Shibata, M., Mori, K., Hamashima, M., 1982. Inhibition of hyphal extension factor formation by
validamycin in Rhizoctonia solani. J. Antibiot. 35 (10), 1422 1423.
Suzuki, Y., 2006. β-Galactosidase deficiency: an approach to chaperone therapy. J. Inherit.
Metab. Dis. 29 (2/3), 471 476.
Suzuki, Y., 2008. Chemical chaperone therapy for GM1-gangliosidosis. Cell. Mol. Life Sci.
65 (3), 351 353.
Suzuki, Y., 2013. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher
disease. Brain Dev. 35 (6), 515 523.
8 Validamycin and Its Derivatives
Suzuki, Y., Ichinomiya, S., Kurosawa, M., Ohkubo, M., Watanabe, H., Iwasaki, H., et al., 2007.
Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis. Ann. Neurol.
62 (6), 671 675.
Trinci, A.P.J., 1984. Antifungal agents which affect hyphal extension and hyphal branching.
Symp. Br. Mycol. Soc. 9 (Mode Action Antifungal Agents), 113 134.
Yuan J., Shao C., Chen D., Ye W.; (Shanghai Laiyi Biopharmaceutical Research and
Development Center Co., Ltd., Peop. Rep. China; Xinchang Pharmaceutical Factory,
Zhejiang Medicine Co., Ltd.). assignee. 2005 20050303. Preparation of valiolamine as
intermediate of voglibose. Application: CN patent 2005-10024194, 1683320.
Chapter 2
Production of Validamycins
2.1 DISCOVERY OF VALIDAMYCINS
In the course of screening for new antibiotics effective in the control of
sheath blight, a destructive disease of rice plants caused by Pellicularia sasa-
kii (Shirai) S. Ito, validamycins were first discovered in the broth of
Streptomyces hygroscopicus var. limoneus T-7545, which was isolated from
a soil sample collected in Akashi City, Hyogo Prefecture, Japan in 1970
(Iwasa et al., 1970). Five years later, they were also discovered in the broth
of S. hygroscopicus var. jinggangensis Yen. TH82, which was isolated from
a soil sample of Jinggang Mountain in Jiangxi, China (Agricultural
Antibiotic Group, 1975). Since then, they have been widely used in Asia as
the rice and wheat protectant against P. sasakii. Now, eight validamycins
have been purified and identified, including A, B, C, D, E, F, G, and H.
(A)
(×950) (×10,000×1/1.5)
(B)
(×7500) (×7500)
FIGURE 2.1 Morphology of S. hygroscopicus var. limoneus T-7545 (A) and S. hygroscopicus
var. jinggangensis Yen. TH82 B. (A) Reprinted with permission courtesy of Japan Antibiotics
Research Association (JARA).
Properties
T-7545 TH82
Temperature and Growth occurs at 1545 C, Growth occurs at 1545.
pH rangesa better growth at 3745 C, no Growth occurs at pH 510,
growth at 10 C and 50 C. better growth at pH 67
Growth occurs at pH 510,
no or poor growth at pH 4,
optimum range pH 67
Gelatin Slow liquefaction Slow liquefaction
Starch Hydrolysis. Diameter of Hydrolysis
hydrolyzed area/diameter of
colony 5 33 mm/8 mm
Tyrosinase Negative Nb
reaction
Litmus milk Peptonization. Coagulation, Peptonization. Coagulation,
doubtful. Reaction, weakly doubtful. Reaction, weakly
acidic acidic
Reduction of Negative (in peptone solution Positive in Czapek’s
nitrate to nitrite and Czapek’s solution) solution. Negative in
peptone solution
(Continued )
16 Validamycin and Its Derivatives
Properties
T-7545 TH82
Cellulose Negative Negative
decomposition
Chromogenicity Negative Negative
Liquefaction of Negative N
serum
Products Validamycins Validamycins and other
antibiotics
a
On glucose asparagine agar.
b
Not tested.
are well utilized for growth. In view of the relatively high optimum tempera-
ture for growth of T-7545 and TH82, the cultural characteristics at 45 C
were observed and compared with those at 28 C. The characteristics at the
higher temperature were found to be almost the same as those at 28 C.
A few properties, such as sparse formation of white aerial mycelium on
Czapek’s agar, Czapek’s glucose agar, Czapek’s glycerol agar, and filter
paper, and a slightly deeper color of the vegetative mycelium on calcium
malate agar, were noted (Table 2.3).
The characteristics of T-7545 and TH82 are summarized as follows: good
growth and abundant aerial mycelia and coiled chains of spores form at
2545 C; on a variety of media, grey to grey and yellow aerial mycelium,
bright yellow to ocher vegetative mycelia and faint, brownish yellow diffus-
ible pigment form; on certain media, black moist spots form in the aerial
mycelium. Dark brown diffusible pigment is not produced on proteinaceous
media, i.e., the strain is nonchromogenic.
Species Length TIR GC Content CDS (No.) Average CDS Coding (%) rRNA Operons tRNA
(bp) (bp) (%) size (bp) (No.) (No.)
S. hygroscopicus 5008 10,145,833 14 71.9 8849 952 83.2 6 68
S. coelicolor A3(2) 8,667,507 21,653 72.1 7825 991 88.9 6 63
S. avermitilis MA-4680 9,025,608 49 70.7 7582 1027 86.3 6 68
S. griseus IFO13350 8,545,929 132,910 72.2 7138 1055 88.1 6 66
S. scabies 87.22 10,148,695 18,488 71.5 8746 1005 86.2 6 75
S. bingchenggensis BCW-1 11,936,683 40,000 70.8 10,023 1031 86.6 6 ND
S. clavuligerus ATCC 27064 6,760,392 ND 72.0 5710 1031 87.1 6 66
a
Data were obtained from GenBank: S. coelicolor A3(2), NC_003888; S. avermitilis MA-4680, NC_003155; S. griseus IFO13350, NC_010572; S. scabies 87.22, NC_013929;
S. bingchenggensis BCW-1, CP002047; S. clavuligerus ATCC 27064, CM000913. ND, not determined.
Production of Validamycins Chapter | 2 19
FIGURE 2.2 Schematic representation of the S. hygroscopicus 5008 chromosome and two
plasmids. (A) The chromosome atlas. The outer scale is numbered in megabases from the left to
the right ends and indicates the core (red) and noncore (blue) chromosomal regions; Circles 1
and 2 (forward and reverse strands), predicted protein coding sequences colored according to
Clusters of Orthologous Groups (COG) function categories; Circles 3 and 4 (forward and reverse
strands), distribution of conserved (red) or strain-specific genes (blue) in 5008 compared with
other Streptomyces chromosomes; Circle 5, distribution of secondary metabolic gene clusters
(red); Circle 6, distribution of tRNA (red) and rRNA operon (blue); Circle 7, GC content; Circle
8, GC bias. Ori, origin of replication. val, validamycin biosynthetic gene cluster. (B) Atlas of lin-
ear plasmid pSHJG1. Circles 1 and 2, predicted coding sequences on the plus and minus strands,
respectively, colored according to COG functional categories; Circle 3, GC content; Circle 4,
GC bias. (C) Atlas of circular plasmid pSHJG2. Circles 1 and 2, predicted coding sequences on
the plus and minus strands, respectively, colored according to COG functional categories; Circle
3, GC content; Circle 4, GC bias.
FIGURE 2.3 Schematic diagram of central carbon and nitrogen metabolisms for validamycin
A production in strain 5008. Red arrows and characters represent metabolic pathways and pre-
cursors directly related to validamycin A biosynthesis, respectively. Numbers in parentheses
indicated copy numbers of annotated proteins or complexes in the metabolic pathways.
Abbreviations: ALD, alanine dehydrogenase; DHAP, dihydroxyacetone phosphate; FBP,
fructose-1, 6-bisphosphate; GAP, glyceraldehyde-3 phosphate; GDH, glutamate dehydrogenase;
Glc, glucose; GlcNAc, N-acetylglucosamine; GOGAT, glutamate synthase; GS, glutamine synthe-
tase; Mal, maltose; PEP, phosphoenolpyruvate.
pH Validamycin pH Validamycin
Titera (unit/mL) Titera (unit/mL)
66 8.0 10,000 7.4 15,000
90 8.0 15,000 7.8 20,000
114 8.2 20,000 8.0 50,000
138 8.6 20,000 8.2 50,000
a
Assayed by dendroid-test method.
b
Composition of the medium used in this experiment was the same as in Table 2.4.
filtration was more difficult and essentially equivalent results were obtained in
a greenhouse test. So the lower temperature was used to prepare the antibiotic.
such as peptone, beef extract, corn steep liquor (CSL), soybean flour (SBF),
and corn gluten meal (CGM) were compared by the reversed layer method.
The results are shown in Table 2.8. Good growth occurred in the media
containing glucose or glycerol as the carbon source regardless of nitrogen
sources.
As for the yield of validamycin, glucose was notably superior to other
carbon sources, and when it was used, no remarkable differences were found
among the nitrogen sources. As a result of repeated examinations, CSL and
CGM were judged relatively better than SBF and beef extract.
When starch was adopted as the carbon source, considerable validamycin
production was obtained, although slowly, in the medium containing CSL
and CGM as the nitrogen sources.
(2) Effects of inorganic salts. Effects of FeSO4, MnSO4, ZnSO4, NaCl,
KCl, and NH4Cl on the production of validamycin were investigated in the
following two kinds of media: (a) 5.0% glucose, 3.0% SBF, 1.0% CSL,
0.5% CaCO3; (b) 4.0% glucose, 2.0% corn starch, 2.0% CSL, 3.0% CGM,
1.5 CaCO3. Little effect of these inorganic salts was found in the first
medium, but in the latter medium, remarkable effects of NaCl and NH4Cl
were found as shown in Table 2.9.
(3) Selection of medium for high yield of validamycins. From these and
other results, a medium composed of glucose 2.0%, corn starch 4.0%, CSL
2.0%, CGM 4.0%, NH4Cl 0.5%, NaCl 1.5%, and CaCO3 1.5% was selected,
yielding about 620 μg/mL of validamycins.
Media
1 2 3 4 5 6 7 8 9 10 11 12
Component Glucose 5 5 5 5
(%)
Glycerol 5 5 5 5
Starch 5 5 5 5
Peptone 1 1 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Beef 0.5 0.5 0.5
extract
CSL 3 3 3 1 1 1 1 1 1
SBF 0.5 0.5 0.5 1 1 1 3 3 3
CGM 3 3 3
NaCl 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
CaCO3 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Growth a
111 111 1 B1 1 111 111 1 1 B1 1 1 111 111 111 111 111 1 B1 1
pH 7.5 7.25 8.0 8.2 7.3 8.3 7.75 7.15 8.0 7.55 8.1 8.6
b
Validamycin titer 64 12.5 12.5 140 12.5 74 103 12.5 38 64 28 12.5
Rf
1.0
0.8
0.6
0.4
0.2
0
1 2 3
FIGURE 2.4 TLC chromatograph of validamycins A and B. Stationary phase: Silica gel G;
Solvent system: n-PrOH/AcOH/H2O 5 4/1/1; Detection: Naphthoresorcin-H2SO4 reagent.
(1) Crude powder of validamycins; (2) Validamycin A; (3) Validamycin B. Reprinted with
permission courtesy of Japan Antibiotics Research Association (JARA).
VA-A
D
A
Refractive index
C
F
B E
0 1 2 3 4 5 6 7 8 9 hours
VA-A
Refractive index
VA-B
0 10 20 30 40 50 60 min.